A Christmas present for Croatia – a Prime Minister Designate.
After the meeting between MOST and HDZ, MOST leader Božo Petrov announced that Tihomir Orešković will be proposed as the Prime Minister-Designate. Deputy Prime Ministers will be representative of the two parties, reports Index.hr on December 23, 2015.
“He is a top professional”, HDZ president Tomislav Karamarko said. “Our conversations will continue, we have agreed that the expertise of candidates will be key. There is no time for experiments and bad decisions. We will follow a reform path”, he added.
“Our priority is for the Prime Minister to be a non-partisan expert. We believe he will be able to choose his own team”, Petrov said, adding that his team will be comprised of people from both MOST and HDZ. “We have made a great choice. In the next month, we will solve everything. I believe it is in everyone’s interests to have as the Prime Minister a person with the greatest potential. If the other side proposes qualified people for positions in Government, we will accept them”, Petrov added.
Orešković was born in 1966 in Zagreb. In 1989, he graduated in chemistry at McMaster University in Canada, and in 1991 he received an MBA focused on finance and information systems. His professional career began in 1992 in the pharmaceutical company Eli Lilly in Canada, where he held various positions in the field of finance and international business, including Latin America and Asia. He left the company as director for relations with the state administration and economic affairs . He then went to work for Novopharm in Canada, which is now a member of the Teva Group, as vice-president of business development, specialty products and chief financial officer. He joined Pliva in 2009 as chief financial officer for Eastern Europe, and in 2010 was appointed to the position of chief financial officer for EMIA region (Eastern Europe, the Mediterranean, Israel and Africa). Until a year ago, Tihomir Orešković was the chief executive officer of Croatian pharmaceutical company Pliva. He currently works for Teva Europe, Pliva’s parent company.
